Subtitle
Secondary Malignancy Risk Following Proton vs. X-ray Radiotherapy of Thymic Epithelial Tumors: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk.
Subtitle
Secondary Malignancy Risk Following Proton vs. X-ray Radiotherapy of Thymic Epithelial Tumors: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk.
Proto therapy Time
May 2022
Executive summary
A modeling study demonstrated significant reduction in secondary malignancy (SM) with the use of PBS relative to both 3DCRT and IMRT for all independent thoracic organs analyzed with the exception of the thyroid gland (p ≤ 0.001). SM rates per 10,000 patients per year per Gy also resulted in significant reductions with the use of PBS relative to 3DCRT and IMRT for the lungs, breasts, and esophagus (p ≤ 0.001). The authors concluded that PBS should therefore be considered in patients diagnosed with thymic malignancies, particularly young female patients.
Key content topics
Top cancer treatments
Related contents
Proton Therapy Publication
November 2020
Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer.
Proton Therapy Publication
October 2023
Comparing the oncologic outcomes of proton therapy and intensity-modulated radiation therapy for head and neck squamous cell carcinoma.
Proton Therapy Publication
January 2024
Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.
Proton Therapy Publication
December 2023
Comparison of the Effectiveness of Radiotherapy with 3D-CRT, IMRT, VMAT and PT for Newly Diagnosed Glioblastoma: A Bayesian Network Meta-Analysis.
Proton Therapy Publication
July 2023
Long-term outcomes of modern multidisciplinary management of sinonasal cancers: The M. D. Anderson experience.
Proton Therapy Publication
November 2022
Pattern of Radiotherapy Treatment in Low-Risk, Intermediate-Risk, and High-Risk Prostate Cancer Patients: Analysis of National Cancer Database.
Proton Therapy Publication
August 2022
Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.
Proton Therapy Publication
October 2022
High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial.
Proton Therapy Publication
October 2022
Systematic Review for Deep Inspiration Breath Hold in Proton Therapy for Mediastinal Lymphoma: A PTCOG Lymphoma Subcommittee Report and Recommendations.